Advertisement

PharmacoEconomics

, Volume 25, Issue 7, pp 537–562 | Cite as

Cost Considerations in the Treatment of Colorectal Cancer

  • Frank G. A. JansmanEmail author
  • Maarten J. Postma
  • Jacobus R. B. J. Brouwers
Review Article

Abstract

Colorectal cancer is among the most common malignancies in developed countries. Screening can reduce mortality significantly, although the most appropriate method is still under debate. Observational studies have revealed that lifestyle measures may also be beneficial for prevention of colorectal cancer.

Surgery is still the most effective treatment modality for colorectal cancer. The survival benefits of chemotherapy are only modest. For nearly 5 decades, 5-fluorouracil (5-FU) has been the main cytotoxic agent for treatment of colorectal cancer. In the last decade, the new cytotoxic agents raltitrexed, irinotecan and oxaliplatin have been introduced, next to the oral 5-FU analogues capecitabine and tegafur in combination with uracil (UFT). Moreover, the immunotherapeutics bevacizumab and cetuximab have become approved for treatment of metastatic colorectal cancer.

The economic implications of colorectal cancer treatment are substantial. The costs of treatment are mainly attributable to the early and terminal stage of the disease (i.e. surgery, hospitalisation, chemo- and immunotherapy and supportive care). The introduction of new chemo- and immunotherapeutics has caused a continuing increase of treatment expenditures. Therefore, comparative costs and cost effectiveness are important for assessing the value of new treatment regimens.

The available study results suggest that addition of irinotecan or oxaliplatin to 5-FU/folinic acid dosage regimens is cost effective. Also, capecitabine is calculated to be cost effective when compared with 5-FU/folinic acid. For UFT, no comparative studies of cost effectiveness were found. Since raltitrexed and 5-FU/folinic acid have shown equal efficacy in terms of survival, cost-effectiveness analysis is considered not to be applicable and cost-minimisation analysis may be sufficient. At present, pharmacoeconomic analyses of combination treatment with the immunotherapeutics bevacizumab or cetuximab are not available, except for recent cost-effectiveness considerations by the UK National Institute for Health and Clinical Excellence with negative recommendations for both agents in the treatment of metastatic colorectal cancer.

Given the high treatment costs, substantial toxicity and relatively limited efficacy of the fast changing chemo- and immunotherapeutic combinations for colorectal cancer, examination of cost-effectiveness studies should be conducted on a routine basis along with determination of clinical benefits.

Keywords

Colorectal Cancer Bevacizumab Irinotecan Oxaliplatin Capecitabine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

No sources of funding were used to assist in the preparation of this review. The authors have no conflicts of interest that are directly relevant to the content of this review.

References

  1. 1.
    Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med 2005; 352: 476–487PubMedCrossRefGoogle Scholar
  2. 2.
    Weitz J, Koch M, Debus J, et al. Colorectal cancer. Lancet 2005; 365: 153–165PubMedCrossRefGoogle Scholar
  3. 3.
    Redaelli A, Cranor CW, Okano GJ, et al. Screening, prevention and socioeconomic costs associated with the treatment of colorectal cancer. Pharmacoeconomics 2003; 21: 1213–1238PubMedCrossRefGoogle Scholar
  4. 4.
    Sobin LH, Wittekind C. UICC: TNM classification of malignant tumours. 6th ed. London: John Wiley & Sons, 2002Google Scholar
  5. 5.
    Greene FL, Balch CM, Fleming ID, et al. AJCC cancer staging handbook. 6th ed. New York (NY): Springer, 2002Google Scholar
  6. 6.
    The Meta-Analysis Group in Cancer. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J Clin Oncol 2004; 22: 3766–3775CrossRefGoogle Scholar
  7. 7.
    Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335–2342PubMedCrossRefGoogle Scholar
  8. 8.
    Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337–345PubMedCrossRefGoogle Scholar
  9. 9.
    Ehrlichman C, Sargent DJ. New treatment options for colorectal cancer. N Engl J Med 2004; 351: 391–392CrossRefGoogle Scholar
  10. 10.
    Mayer RJ. Two steps forward in the treatment of colorectal cancer. N Engl J Med 2004; 350: 2406–2408PubMedCrossRefGoogle Scholar
  11. 11.
    Schrag D. The price tag on progress: chemotherapy for colorectal cancer. N Engl J Med 2004; 351: 317–319PubMedCrossRefGoogle Scholar
  12. 12.
    Rajpal S, Venook AP. Targeted therapy in colorectal cancer. Clin Adv Hematol Oncol 2006; 4: 124–132PubMedGoogle Scholar
  13. 13.
    Grem JL. Mature results of adjuvant colon cancer trials from the fluorouracil-only area. J Natl Cancer Inst 2004; 96: 727–729PubMedCrossRefGoogle Scholar
  14. 14.
    Gill S, Loprinzi CL, Sargent DJ, et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 2004; 22: 1773–1775CrossRefGoogle Scholar
  15. 15.
    Schrag D, Rifas-Shiman S, Saltz L, et al. Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer. J Clin Oncol 2002; 20: 3999–4005PubMedCrossRefGoogle Scholar
  16. 16.
    Folprecht G, Cunningham D, Ross P, et al. Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. Ann Oncol 2004; 15: 1330–1338PubMedCrossRefGoogle Scholar
  17. 17.
    Golfinopoulos V, Pentheroudakis G, Pavlidis N. Treatment of colorectal cancer in the elderly: a review of the literature. Cancer Treat Rev 2006; 32: 1–8PubMedCrossRefGoogle Scholar
  18. 18.
    Simmonds PC. Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. Colorectal Cancer Collaborative Group. BMJ 2000; 321: 531–535PubMedCrossRefGoogle Scholar
  19. 19.
    Grothey A, Sargent D, Goldberg RM, et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004; 22: 1209–1214PubMedCrossRefGoogle Scholar
  20. 20.
    International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 1995; 345: 939–944CrossRefGoogle Scholar
  21. 21.
    Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350: 2343–2351PubMedCrossRefGoogle Scholar
  22. 22.
    Mayor S. NICE rules on chemotherapy drugs for colon and breast cancer. BMJ 2006; 332: 1052PubMedCrossRefGoogle Scholar
  23. 23.
    Maroun JA, Asche C, Romeyer F, et al. A cost comparison of oral tegafur plus uracil/folinic acid and parenteral fluorouracil for colorectal cancer in Canada. Pharmacoeconomics 2003; 21: 1039–1051PubMedCrossRefGoogle Scholar
  24. 24.
    Pasetto LM, Jirillo A, Iadicicco G, et al. FOLFOX versus FOLFIRI: a comparison of regimens in the treatment of colorectal cancer metastases. Anticancer Res 2005; 25: 563–576PubMedGoogle Scholar
  25. 25.
    Limat S, Bracco-Nolin CH, Legat-Fagnoni C, et al. Economic impact of simplified de Gramont regimen in first-line therapy in metastatic colorectal cancer. Eur J Health Econ 2006; 7: 107–113PubMedCrossRefGoogle Scholar
  26. 26.
    Focan C. Pharmaco-economic comparative evaluation of combination chronotherapy vs standard chemotherapy for colorectal cancer. Chronobiol Int 2002; 19: 289–297PubMedCrossRefGoogle Scholar
  27. 27.
    Ward S, Kaltenthaler E, Cowan J, et al. Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation. Health Technol Assess 2003; 7: 1–93PubMedGoogle Scholar
  28. 28.
    Ward SE, Kaltenhaler E, Cowan J, et al. The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer. Br J Cancer 2006; 95: 27–34PubMedCrossRefGoogle Scholar
  29. 29.
    Jansman FGA, Postma MJ, Van Hartskamp D, et al. Cost-benefit analysis of capecitabine versus 5-fluorouracil/leucovorin in the treatment of colorectal cancer in The Netherlands. Clin Ther 2004; 26: 579–589PubMedCrossRefGoogle Scholar
  30. 30.
    Hieke K, Kleeberg UR, Stauch M, et al. Costs of treatment of colorectal cancer in different settings in Germany. Eur J Health Econ 2004; 5: 270–273PubMedCrossRefGoogle Scholar
  31. 31.
    Hale JP, Cohen DR, Maughan TS, et al. Costs and consequences of different chemotherapy regimens in metastatic colorectal cancer. Br J Cancer 2002; 86: 1684–1690PubMedCrossRefGoogle Scholar
  32. 32.
    Sculpher M, Palmer MK, Heyes A. Costs incurred by patients undergoing advanced colorectal cancer therapy. Pharmacoeconomics 2000; 17: 361–370PubMedCrossRefGoogle Scholar
  33. 33.
    Norum J, Balteskard L, Edna TH, et al. Raltitrexed (Tomudex) or Nordic-FLv regimen in metastatic colorectal cancer: a randomized phase II study focusing on quality of life, patients’ preferences and health economics. J Chemother 2002; 14: 3018Google Scholar
  34. 34.
    Hillner BE, Schrag D, Sargent DJ, et al. Cost-effectiveness projections of oxaliplatin and infusional fluorouracil versus irinotecan and bolus fluorouracil in first-line therapy for metastatic colorectal carcinoma. Cancer 2005; 104: 1871–1884PubMedCrossRefGoogle Scholar
  35. 35.
    Earle CC, Kwok A, Scott Gazelle G, et al. Two schedules of second-line irinotecan for metastatic colon carcinoma: economic evaluation of a randomized trial. Cancer 2004; 101: 2533–2539PubMedCrossRefGoogle Scholar
  36. 36.
    Lloyd-Jones M, Hummel S, Bansback N, et al. A rapid and systematic review of the evidence for the clinical effectiveness and cost-effectiveness of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer. Health Technol Assess 2001; 5: 1–128Google Scholar
  37. 37.
    Koperna T, Semmler D. Innovative chemotherapies for stage III colon cancer: a cost-effectiveness study. Hepatogastroenterol 2003; 50: 1903–1909Google Scholar
  38. 38.
    Levy-Piedbois C, Durand-Zaleski I, Juhel H, et al. Cost-effectiveness of second-line treatment with irinotecan or infusional 5-fluorouracil in metastatic colorectal cancer. Ann Oncol 2000; 11: 157–161PubMedCrossRefGoogle Scholar
  39. 39.
    Cunningham D, Falk S, Jackson D. Clinical and economic benefits of irinotecan in combination with 5-fluorouracil and folinic acid as first line treatment of metastatic colorectal cancer. Br J Cancer 2002; 86: 1677–1683PubMedCrossRefGoogle Scholar
  40. 40.
    Iveson TJ, Hickish T, Schmitt C, et al. Irinotecan in second-line treatment of metastatic colorectal cancer: improved survival and cost-effect compared with infusional 5-FU. Eur J Cancer 1999; 35: 1796–1804PubMedCrossRefGoogle Scholar
  41. 41.
    Cassidy J, Douillard JY, Twelves C, et al. Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes’ C colon cancer: the X-ACT trial. Br J Cancer 2006; 94: 1122–1129PubMedCrossRefGoogle Scholar
  42. 42.
    Groener MGH, Van Ineveld BM, Byttebier G, et al. An economic evaluation of Tomudex (raltitrexed) and 5-fluorouracil plus leucovorin in advanced colorectal cancer. Anticancer Drugs 1999; 10: 283–288PubMedCrossRefGoogle Scholar
  43. 43.
    Norum J, Vonen B, Olsen JA, et al. Adjuvant chemotherapy (5-fluorouracil and levamisole) in Dukes’ B and C colorectal carcinoma: a cost-effectiveness analysis. Ann Oncol 1997; 8: 65–70PubMedCrossRefGoogle Scholar
  44. 44.
    Monz BUM, König HH, Leidl R, et al. Cost effectiveness of adding folinic acid to fluorouracil plus levamisole ad adjuvant chemotherapy in patients with colon cancer in Germany. Pharmacoeconomics 2003; 21: 709–719PubMedCrossRefGoogle Scholar
  45. 45.
    Durand-Zaleski I, Roche B, Buyse M, et al. Economic implications of hepatic arterial infusion chemotherapy in treatment of nonresectable colorectal liver metastases. J Natl Cancer Inst 1997; 89: 790–795PubMedCrossRefGoogle Scholar
  46. 46.
    Durand-Zaleski I, Earlam S, Fordy C, et al. Cost-effectiveness of systemic and regional chemotherapy for treatment of patients with unresectable colorectal liver metastases. Cancer 1998; 83: 882–888PubMedCrossRefGoogle Scholar
  47. 47.
    Jansman FGA, Postma MJ. Costs of chemotherapy in the treatment of colorectal cancer. Eur J Health Econ 2006; 7: 145–146PubMedCrossRefGoogle Scholar
  48. 48.
    Matasar MJ, Sundararajan V, Grann VR, et al. Managing of colorectal cancer in elderly patients: focus on the cost of chemotherapy. Drugs Aging 2004; 21: 113–133PubMedCrossRefGoogle Scholar
  49. 49.
    Van den Hout WB, Van den Brink M, Stiggelhout AM, et al. Cost-effectiveness analysis of colorectal cancer treatment. Eur J Cancer 2002; 38: 953–963CrossRefGoogle Scholar
  50. 50.
    Ramsey SD, Berry K, Etzioni R. Lifetime cancer-attributable cost of care for long-term survivors of colorectal cancer. Am J Gastroenterol 2002; 97: 440–445PubMedCrossRefGoogle Scholar
  51. 51.
    Paramore LC, Thomas SK, Knopf KB, et al. Estimating costs of care for patients with newly diagnosed metastatic colorectal cancer. Clin Colorectal Cancer 2006; 6: 52–58PubMedCrossRefGoogle Scholar
  52. 52.
    Kerrigan M, Howlader N, Mandelson MT, et al. Costs and survival of patients with colorectal cancer in a health maintenance organization and a preferred provider organization. Med Care 2005; 43: 1043–1048PubMedCrossRefGoogle Scholar
  53. 53.
    Fireman BH, Quesenberry CP, Somkin CP, et al. Cost of care for cancer in a health maintenance organization. Health Care Financ Rev 1997; 18: 51–76PubMedGoogle Scholar
  54. 54.
    Seifeldin R, Hantsch JJ. The economic burden associated with colon cancer in the United States. Clin Ther 1999; 21: 1370–1379PubMedCrossRefGoogle Scholar
  55. 55.
    Etzioni R, Ramsey SD, Berry K, et al. The impact of including future medical care costs when estimating the costs attributable to a disease: a colorectal cancer case study. Health Econ 2001; 10: 245–256LPubMedCrossRefGoogle Scholar
  56. 56.
    Brown ML, Riley GF, Potosky AL, et al. Obtaining long-term disease specific costs of care: application to Medicare enrollees diagnosed with colorectal cancer. Med Care 1999; 37: 1249–1259PubMedCrossRefGoogle Scholar
  57. 57.
    Yabroff KR, Warren JL, Knopf K, et al. Estimating patient time costs associated with colorectal cancer care. Med Care 2005; 43: 640–648PubMedCrossRefGoogle Scholar
  58. 58.
    O’Brien BD, Brown MG, Kephart G. Estimation of hospital costs for colorectal cancer care in Nova Scotia. Can J Gastroenterol 2001; 15: 143–147Google Scholar
  59. 59.
    Delco F, Egger R, Bauerfeind P, et al. Hospital health care resource utilization and costs of colorectal cancer during the first 3-year period following diagnosis in Switzerland. Aliment Pharmacol Ther 2005; 21: 615–622PubMedCrossRefGoogle Scholar
  60. 60.
    Bouvier V, Reaud JM, Gignoux M, et al. Cost of diagnostic and therapeutic management of colorectal cancer according to stage at diagnosis in the Calvados Departement, France. Eur J Health Econ 2003; 4: 102–106PubMedCrossRefGoogle Scholar
  61. 61.
    Geddes M, Carli S, Ercolanelli M, et al. Colorectal, lung, and breast cancer care during the three years following the diagnosis: a population-based study. Tumori 1996; 82: 210–214PubMedGoogle Scholar
  62. 62.
    Audisio RA, Cazzaniga M, Robertson C, et al. Elective surgery for colorectal cancer in the aged: a clinical-economical evaluation. Br J Cancer 1997; 76: 382–384PubMedCrossRefGoogle Scholar
  63. 63.
    Neymark N, Adriaenssen I. The costs of managing patients with advanced colorectal cancer in 10 different European centres. Eur J Cancer 1999; 35: 1789–1795PubMedCrossRefGoogle Scholar
  64. 64.
    Schrag D, Weeks J. Costs and cost-effectiveness of colorectal cancer prevention and therapy. Semin Oncol 1999; 26: 561–568PubMedGoogle Scholar
  65. 65.
    Bang H. Medical cost analysis: application to colorectal cancer data from the SEER Medicare database. Contemp Clin Trials 2005; 26: 586–597PubMedCrossRefGoogle Scholar
  66. 66.
    Twelves C, Boyer M, Findlay M, et al. Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma. Eur J Cancer 2001; 37: 597–604PubMedCrossRefGoogle Scholar
  67. 67.
    Giuliani G, Lucioni C, Mazzi S, et al. Economic evaluation of oral capecitabine vs intravenous 5-fluorouracil plus leucovorin (Mayo regimen) in the treatment of advanced colorectal cancer [in Italian]. Pharmacoeconomics 2002; 4: 31–38Google Scholar
  68. 68.
    Murad AM, Augusto de Andrade C, Delfino C, et al. Pharmacoeconomic evaluation of tegafur-uracil (UFT) vs fluorouracil for the management of colorectal cancer in Brazil and Argentina. Clin Drug Invest 1997; 13: 90–98CrossRefGoogle Scholar
  69. 69.
    Ron IG, Lotan A, Inbar MJ, et al. Advanced colorectal carcinoma: redefining the role of oral ftorafur. Anticancer Drugs 1996; 7: 649–654PubMedCrossRefGoogle Scholar
  70. 70.
    Provenzale D, Gray RN. Colorectal cancer screening and treatment: review of outcomes research. J Natl Cancer Inst Monogr 2004; 33: 45–55PubMedCrossRefGoogle Scholar
  71. 71.
    Earle CC, Chapman RH, Baker CS, et al. Systematic overview of cost-utility assessments in oncology. J Clin Oncol 2000; 18: 3302–3317PubMedGoogle Scholar
  72. 72.
    Cavallo MC, Gerzeli S, De Carli C, et al. The cost of treatment for advanced colorectal cancer: a retrospective comparison of five chemotherapy regimens used in a Northern Italy hospital [in Italian]. Pharmacoeconomics 2001; 3: 49–59Google Scholar
  73. 73.
    Nicholls C, Cassidy J, Freemantle N, et al. Cost-effectiveness of combination chemotherapy (oxaliplatin or irinotecan in combination with 5-FU/FA) compared with 5-FU/FA alone. J Drug Assess 2001; 4: 215–226Google Scholar
  74. 74.
    Nicholls C, Cassidy J, Freemantle N, et al. Cost-effectiveness of oxaliplatin in combination with 5-FU/FA compared with 5-FU/FA alone. J Drug Assess 2001; 4: 255–263Google Scholar
  75. 75.
    Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22: 23–30PubMedCrossRefGoogle Scholar
  76. 76.
    Fuchs CS, Moore MR, Harker G, et al. Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol 2003; 21: 807–814PubMedCrossRefGoogle Scholar
  77. 77.
    L’informatore farmaceutico 2003: annuario italiano dei medicamenti e dei laboratori. Italian directory of medicines and manufacturers. 63rd ed. 5 Vol. Milan: OEMF International SRL, 2003Google Scholar
  78. 78.
    National Institute for Health and Clinical Excellence. Colorectal cancer (metastatic): bevacizumab and cetuximab (technology appraisal TA118) [online]. Available from URL: http://www. nice.org.uk/ta118 [Accessed 2007 May 16]Google Scholar
  79. 79.
    National Institute for Health and Clinical Excellence. Colorectal cancer (advanced): irinotecan, oxaliplatin and raltitrexed (review) [technology appraisal TA118] (online). Available from URL: http://www.nice.org.uk/ta093 [Accessed 2007 May 16]Google Scholar
  80. 80.
    National Institute for Health and Clinical Excellence. Colorectal cancer: capecitabine and tegafur uracil (technology appraisal TA61) [online]. Available from URL: http://www.nice.org.uk/ta061 [Accessed 2007 May 1 ]Google Scholar
  81. 81.
    Jansman FGA, Sleijfer DT, Coenen JLLM, et al. Risk factors determining chemotherapeutic toxicity in patients with advanced colorectal cancer. Drug Safety 2000; 23: 255–278PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2007

Authors and Affiliations

  • Frank G. A. Jansman
    • 1
    • 2
    Email author
  • Maarten J. Postma
    • 3
  • Jacobus R. B. J. Brouwers
    • 1
  1. 1.Groningen University Institute for Drug Exploration (GUIDE), Department of Pharmacotherapy & Pharmaceutical CareUniversity of GroningenGroningenThe Netherlands
  2. 2.Department of Clinical PharmacyIsala KliniekenZwolleThe Netherlands
  3. 3.Groningen University Institute for Drug Exploration (GUIDE), Department of Social Pharmacy & PharmacoepidemiologyUniversity of GroningenGroningenThe Netherlands

Personalised recommendations